SPY749.60−0.63%QQQ674.26−0.83%BTC/USD65,340.70−4.24%DIA520.13−0.58%GLD355.70+0.07%TLT79.42+0.05%

NovoCure Ltd

NVCRNASDAQ

Trade with Public

$11.83

0.110.94%

At close: Nov 13, 4:00 PM EST

$11.83

N/A

After Hours: 4:00 PM EST

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

NovoCure (NVCR) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for NovoCure (NVCR) stock.

Analyst Consensus — 7 Analysts

4Buy

3Hold

# Analysts7

Latest Upgrades and Downgrades for NovoCure Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Ladenburg Thalmann	Kevin DeGeeter	PT Raise	Buy	$27→$31
—	Wedbush	David Nierengarten	PT Cut	Neutral	$20→$19
—	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$20→$15
—	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$23→$20
—	Wedbush	David Nierengarten	PT Raise	Neutral	$18→$20
—	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$46→$52
—	JP Morgan	Jessica Fye	Reinstates	Neutral	$17
—	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$48→$46
—	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$14→$17
—	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$16→$20
—	Wedbush	David Nierengarten	Maintained	Neutral	$18
—	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$47→$49
—	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$39→$47
—	Wedbush	David Nierengarten	Maintained	Neutral	$18
—	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$42→$39
—	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$38→$42
—	JP Morgan	Jessica Fye	PT Cut	Neutral	$25→$23
—	Wells Fargo	Larry Biegelsen	Downgrade	Overweight→Equal-Weight	$40→$15
—	Ladenburg Thalmann	Kevin DeGeeter	Initiate	Buy	$30
—	Piper Sandler	Jason Bednar	Maintained	Overweight	$34

NovoCure Ltd

NovoCure (NVCR) Stock Price Target 2026

Latest Upgrades and Downgrades for NovoCure Stock

NovoCure (NVCR) Stock Price Target 2026

Latest Upgrades and Downgrades for NovoCure Stock

Analyst Ratings News

PRO
Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31

PRO
Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19

PRO
Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15

PRO
Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20

PRO
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31

PRO
Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19

PRO
Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15

PRO
Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20

PRO
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52

NovoCure Ltd

NovoCure (NVCR) Stock Price Target 2026

Latest Upgrades and Downgrades for NovoCure Stock

NovoCure (NVCR) Stock Price Target 2026

Latest Upgrades and Downgrades for NovoCure Stock

Analyst Ratings News

PROLadenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31

PROWedbush Maintains Neutral on NovoCure, Lowers Price Target to $19

PROWells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15

PROEvercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20

PROWedbush Maintains Neutral on NovoCure, Raises Price Target to $20

PROHC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52

People Also Watch

People Also Watch

Analyst Ratings News

PROLadenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31

PROWedbush Maintains Neutral on NovoCure, Lowers Price Target to $19

PROWells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15

PROEvercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20

PROWedbush Maintains Neutral on NovoCure, Raises Price Target to $20

PROHC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52

PRO
Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31

PRO
Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19

PRO
Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15

PRO
Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20

PRO
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52

PRO
Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31

PRO
Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19

PRO
Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15

PRO
Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20

PRO
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52